Your task is to predict the verdict of a claim based on the provided question-answer pair evidence. The possible labels are: 'Supported', 'Refuted', 'Not Enough Evidence', 'Conflicting Evidence/Cherrypicking'. Justify your answer using the provided evidence and select the correct label.

Claim: South Africa has “expertise in the development and trial of a range of vaccines”

Q1: What is an example of research work carried out in South Africa?
A1: The American Society for Microbiology Journals published online on April 3, 2019, a research paper entitled Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus written by authors from South Africa's
Institute of Infectious Disease and Molecular Medicine, Faculty of Health Science, University of Cape Town, Cape Town, South Africa;
Division of Medical Virology, Department of Pathology, University of Cape Town, Cape Town, South Africa;
Centre for HIV and STIs, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa;
Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa;
Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Congella, South Africa;
Biopharming Research Unit, Department of Molecular and Cell Biology, University of Cape Town, Cape Town, South Africa

Q2: Who is Biovac?
A2: Headquartered in Cape Town, the Biovac Institute is the result of a partnership formed with the South African government in 2003 to establish vaccine manufacturer in South Africa. The company partners with various organisations across the vaccine value chain, from development to manufacturing and distribution..

Q3: What technology packages has Biovac developed to create bacterial vaccines?
A3: We have developed a technology package for the manufacture of Haemophilus influenzae type b (Hib) conjugate vaccine. To date, this has been transferred to two international vaccine manufacturers. One of our partners has successfully commercialised a pentavalent vaccine containing Diphtheria, Tetanus, Pertussis, Hepatitis B, Haemophilus influenzae b (DTP-HepB-Hib) using our conjugate Hib vaccine technology. The second partner has started clinical trials.
user
justification: There are institutions in South Africa with adequate facilities that deals in vaccine value chain, from development to manufacturing and distribution. 

verdict: 'Supported'
assistant